The FT819 data showing efficacy without conditioning chemotherapy is a significant differentiator in the competitive CAR T landscape. Monitor for additional FT819 dose level 2 data and potential regulatory alignment for registrational path. FT839 and FT836 preclinical data support pipeline optionality but are early stage.
FATE drugs
FATE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $2.18entry
- T+1 · 6mo ago +3.21%α +3.35% · $2.25
- T+5 · 6mo ago −20.64%α −20.56% · $1.73
- T+20 · 5mo ago −12.84%α −12.54% · $1.90
- T+60 · 3mo ago +19.27%α +14.87% · $2.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell programs. FT819 showed 3/3 SLE patients achieving SRI-4 and 2/3 achieving LLDAS with durable B-cell remodeling up to 12 months without conditioning chemotherapy. Preclinical data for FT839 and FT836 demonstrated broad depletion of pathogenic cells and synergy with standard-of-care therapies. The data supports the company's platform approach to eliminate conditioning chemotherapy, potentially expanding patient access.
Key Facts
- FT819: 3/3 SLE patients achieved SRI-4, 2/3 achieved LLDAS at dose level 1 without conditioning chemotherapy.
- FT819: 79% average depletion of major B cell clones lasting up to 12 months post single dose.
- FT839 preclinical: >99% depletion of B cells, plasmablasts, plasma cells; >90% depletion of activated T cells in RA and SLE samples.
- FT839: Persistence enhanced ~60x vs. unmodified CAR T via Sword and Shield technology.
- FT836 preclinical: Up to 100% tumor control in xenograft models as monotherapy or with mAbs; cytolytic activity enhanced ~5x with chemo/radiotherapy.
- FT836: Phase 1 clinical trials ongoing in solid tumors (NCT07216105) and multiple myeloma (NCT07221032).
- FT819 dose level 2 (900M cells) enrollment initiated.
Financial Impact
No financial figures disclosed in press release. Positive clinical data may support future regulatory filings and partnership opportunities.
Risk Factors
- Clinical data is early-stage (Phase 1, small sample size) and may not replicate in larger trials.
- FT819 dose level 2 data not yet available; higher doses may have safety or efficacy issues.
- FT839 and FT836 are preclinical; clinical validation is years away.
- Company has no approved products and relies on future financing or partnerships.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291886 |
Track record
21 reports on FATE
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers